People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026

ConferencepositiveWegovy® pillPositive

AI Analysis

Summary

Real-world data presented at EASD2026 showed patients switching from injectable GLP-1 therapies to Novo Nordisk's oral semaglutide (Wegovy® pill) achieved an average weight loss of 4.1% body weight after three months.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Real-world data showed patients switching from injectable GLP-1 therapies to oral semaglutide lost an average of 4.1% body weight (4.0 kg/8.8 lb) after three months

Importance:5/10

Sentiment:

0.70

GLP-1weight lossoral formulationreal-world dataEASD conference

Related Companies

$NVO

Read the original article

Published by PR Newswire Biotech on September 30, 2026 9:45 AM

Read Original